We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Spectrum Asks FDA to Revise Fusilev Approval Date, Extend Exclusivity
Spectrum Asks FDA to Revise Fusilev Approval Date, Extend Exclusivity
Spectrum Pharmaceuticals wants an extra four months of market exclusivity on its cancer drug Fusilev, arguing the FDA’s delay in approving the drug’s name entitles it to a revised approval clock.